News
8h
InsideHook on MSNCompounding Controversy Breaks Up Novo Nordisk-Hims & Hers PartnershipAs GLP-1 drugs like Wegovy and Ozempic grow in popularity, so too has a kind of alternative: compounded versions of the drugs ...
There is a bottomless appetite for news about weight-loss drugs. We cannot hear enough about the celebrities, politicians and ...
Hims & Hers extended its rally for the second day on Friday, adding 6.76 percent to close at $49.41 apiece after its chief ...
The market for weight management medicines has been the hottest therapeutic area in the past two years. The pharmaceutical giant has far too much going its way. Analysts predict that the weight ...
A fast-growing group of Americans are turning to what many call the "gray market" for obesity medicines, bringing cheap ...
San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...
Novo Nordisk A/S (NYSE:NVO) is one of the 12 stocks that will make you rich in 10 years. On June 23, the company discontinued its partnership with Hims & Hers concerning selling its weight-loss drug, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results